Skip to main content
SpringerLink
Log in

The role of chemotherapy including ifosfamide for ovarian carcinoma

  • Ifosfamide, Chemotherapy, Ovarian Carcinoma
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

On the basis of the results of earlier studies, 30 departments of gynecology have been cooperating nationwide in Austria since 1980 to promote the use of adjuvant chemotherapy after surgery for cure of ovarian carcinoma in early stages and the role of lymph node dissection and of second-look operation. Results recorded in more than 160 patients treated with adjuvant chemotherapy after so-called radical surgery performed in disease stages I and II demonstrate that only highly differentiated tumours in stage Ia can be cured by surgery only with no further adjuvant treatment. This underlines the necessity for staging. More than 200 patients with TNM stages III and IV were randomized after debulking surgery to receive treatment with different kinds of drug combinations to compare the therapeutic efficacy of a sequential alternating drug regimen consisting of Adriamycin-cisplatin+vincristine-cyclophosphamide+high-dose methotrexate with that of the combination of Adriamycin-cyclophosphamide and that of Adriamycin-cisplatin. High-dosed ifosfamide was also used in pilot studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brade W, Seeber S, Herdrich K (1986) Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother Pharmacol 18 [Suppl 2]:S1-S9

    Google Scholar 

  2. Bramwell VHC, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, Van Oosterom A (1987) Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311–321

    Google Scholar 

  3. Brock N (1989) Oxazaphosphorine cytostatics: past-present-future. Cancer Res 49:1–7

    Google Scholar 

  4. Dittrich C, Salzer H, Sevelda P, Gitsch E, Karrer K, Rainer H, Moser K, and Austrian Collaborative Ovarian Cancer Study Group (1985) Prospective randomized trial in ovarian cancer of stages III and IV: changing scheme (Adriamycin/cistatin — vincristine/cyclophosphamide — high-dose methotrexate) versus A/P (Adriamycin/cisplatin) versus A/C (Adriamycin/cyclophosphamide). In: Recent advances in chemotherapy — anticancer section. University of Tokyo Press, Tokyo

    Google Scholar 

  5. Gitsch E, Salzer H, Schönbauer M, Langer M, Smekal G, Karrer K, Moser K, Rainer H, Dittrich C, Schemper M, and Austrian Collaborative Study Group for the Treatment of Ovarian Cancer (1983) Preliminary results of a randomized cooperative trial in Austria. Five-drug sequential therapy versus standard chemotherapy in ovarian cancer stage III and IV. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 28. 8. 1983 to 2. 9. 1983

  6. Howell SB, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE, Weiss RJ (1987) Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 5:1607–1612

    Google Scholar 

  7. Mulder POM, Willemse PHB, Aalders JG, De Vries EGE, Sleijfer DT, Smith Sibinga TC, Mulder NH (1989) High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 25:645

    Google Scholar 

  8. Omura GA, Bundy BN, Berek JS, Curry H, Delgado G, Mortel R (1989) Randomized trial of cyclophosphamide plus cisplation with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 7:457–465

    Google Scholar 

  9. Ozols RF, Young RC (1984) Chemotherapy of ovarian cancer. Semin Oncol 11:251–263

    Google Scholar 

  10. Podratz KC, Malkasian GD, Hilton JF, harris EA, Gaffey TA (1985) Second-look laparotomy in ovarian cancer: evaluation of pathologic variables. Am J Obstet Gynecol 8:152–230

    Google Scholar 

  11. Rubin SC, Hoskins WJ, Hakes TB, Markman M, Reichman BS, Chapman D, Lewis JL (1989) Serum Ca 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 160:667–671

    Google Scholar 

  12. Salzer H, Gitsch E, Schönbauer M, Langer M, Smekal G, Karrer K, Moser K, Rainer H, Dittrich C, Schemper M (1983) Cooperative treatment of ovarian cancer stage I–IV. Preliminary results in 226 patients randomized nationwide. Proceedings of the 13th International Congress of Chemotherapy, Vienna, 28. 8. 1983 to 2. 9. 1983

  13. Salzer H, Gitsch E, Dittrich C, Sevelda P, Karrer K, Schemper M, Stempel-Smekal G, Langer M, Wagner G, Rainer H, Moser K, Czerwenka K, Breitenecker G, Spona J, und Osterreichische Arbeitsgemeinschaft zur Therapie des Ovarialkarzinoms (1985) Ergebnisse der ersten multizentrischen österreichischen Ovarialkarzinomstudie: Prospektiv randomisierter Vergleich einer sequentiellen Chemotherapie (Adriamycin/Cisplatin-Vincristin/Cyclophosphamid-Methotrexat) mit 2 Standard-Schemata (Adriamycin/Cyclophosphamid oder Adriamycin/Cisplatin) bei Patientinnen der Stadien III and IV. Geburtsh Frauenheilkd 45:761–768

    Google Scholar 

  14. Salzer H, Dittrich C, Sevelda P, Gitsch E, Karrer K, Rainer H, Moser K and Austrian Collaborative Ovarian Cancer Study Group (1986) Prospective randomized trial in ovarian cancer of the stages III and IV: changing-scheme versus A/P versus A/C. In: Abstracts of lectures, symposia and free communications of the 14th International Cancer Congress, Budapest, 21–27. 8. 1986 vol 3

  15. Schieder K, Kölbl H, Bieglmayer C, Breitenecker G (1987) Heterogene Verteilung von Steroidhormonrezeptoren bei Ovarial- und Endometriummalignomen. Tumor Diagn Ther 8:171–176

    Google Scholar 

  16. Sevelda P, Salzer H, Dittrich C, Moser K, Karrer K, Gitsch E (1986) A prospective randomized study of ovarian patients stage I and II: radiation therapy versus chemotherapy-radiation combined modality treatment. in: Abstracts of lectures, symposia and free communications of the 14th International Cancer Congress, Budapest, 21–27. 8. 1986, Budapest, vol 3

  17. Sevelda P, Dittrich C, Salzer H (1989) The value of second-look operation in patients with advanced epithelial ovarian carcinoma. Arch Gynecol Obstet 244:79–86

    Google Scholar 

  18. Spona J, Gitsch E, Salzer H, Karrer K, and Collaborative Study Group (1983) Estrogen and gestagen receptors in ovarian carcinoma. Gynecol Obstet Invest 16:189–198

    Google Scholar 

  19. Thipgen JT, Vance RB, Lambuth BW (1988) Ovarian carcinoma: the role of chemotherapy. Semin Oncol 15 [Suppl 3]:16–23

    Google Scholar 

  20. Voest EE, Van Houwelingen JC, Neijt JP (1989) A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival [measured with the log (relative risk)] as main objectives. Eur J Cancer Clin Oncol 25:711

    Google Scholar 

  21. Wiltshaw E, Raju KS, Dawson J and The Ovarian Tumor Group, Royal Marsden Hospital, London (1985) The role of cytoreductive surgery in advanced carcinoma of the ovary: an analysis of primary and second surgery. Br J Obstet Gynecol 92:522 CC, 28/25, 234

    Google Scholar 

  22. Zalupski M, Baker LH (1988) Ifosfamaide. JNCI 80:556–566

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemotherapy, University of Vienna, Austria

    K. Karrer, H. Salzer, P. Sevelda & C. Dittrich

  2. Institute for Epidemiology of Neoplasms, University of Vienna, Borschkegasse 81, A-1090, Vienna, Austria

    K. Karrer, H. Salzer, P. Sevelda & C. Dittrich

Authors
  1. K. Karrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Salzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Sevelda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Dittrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Austrian Collab. Ovarian Cancer Study Group

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karrer, K., Salzer, H., Sevelda, P. et al. The role of chemotherapy including ifosfamide for ovarian carcinoma. Cancer Chemother. Pharmacol. 26 (Suppl 1), S30–S32 (1990). https://doi.org/10.1007/BF00685413

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685413

Keywords

Search

Navigation